Management of mood and anxiety disorders in patients receiving opioid agonist therapy: Review and meta-analysis

2017 ◽  
Vol 26 (6) ◽  
pp. 551-563 ◽  
Author(s):  
Ahmed N. Hassan ◽  
Aaron S. Howe ◽  
Andriy V. Samokhvalov ◽  
Bernard Le Foll ◽  
Tony P. George
Keyword(s):  
Anxiety Disorders ◽  
Meta Analysis ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy ◽  
Mood And Anxiety Disorders

scholarly journals Association between opioid agonist therapy and testing, treatment uptake, and treatment outcomes for hepatitis C infection among people who inject drugs: A systematic review and meta-analysis

2020 ◽  
Author(s):  
Jason Grebely ◽  
Lucy Tran ◽  
Louisa Degenhardt ◽  
Alexander Dowell-Day ◽  
Thomas Santo ◽  
...  
Keyword(s):  
Treatment Outcomes ◽  
People Who Inject Drugs ◽  
Meta Analysis ◽  
Hcv Rna ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy ◽  
Treatment Uptake ◽  
Hcv Antibody ◽  
Hcv Testing

Abstract Background People who inject drugs (PWID) experience barriers to accessing testing and treatment for hepatitis C virus (HCV) infection. Opioid agonist therapy (OAT) may provide an opportunity to improve access to HCV care. This systematic review assessed the association of OAT and HCV testing, treatment, and treatment outcomes among PWID. Methods Bibliographic databases and conference presentations were searched for studies assessing the association between OAT and HCV testing, treatment, and treatment outcomes [direct-acting antiviral (DAA) therapy only] among people who inject drugs (in the past year). Meta-analysis was used to pool estimates. Results Among 9,877 articles identified, 22 studies conducted in Australia, Europe, North America, and Thailand were eligible and included. Risk of bias was serious in 21 studies and moderate in one study. Current/recent OAT was associated with an increased odds of recent HCV antibody testing [4 studies; odds ratio (OR), 1.80; 95% CI:1.36, 2.39), HCV RNA testing among those who were HCV antibody positive (2 studies; OR, 1.83; 95% CI:1.27, 2.62), and DAA treatment uptake among those who were HCV RNA positive (7 studies; OR 1.53; 95% CI: 1.07, 2.20). There was insufficient evidence of an association between OAT and treatment completion (9 studies) or sustained virologic response following DAA therapy (9 studies). Conclusions Opioid agonist therapy can increase linkage to HCV care, including uptake of HCV testing and treatment among PWID. This supports the scale-up of OAT as part of strategies to enhance HCV treatment to further HCV elimination efforts.

950 Association between capacity for maternal opioid agonist therapy treatment and neonatal abstinence syndrome

2021 ◽  
Vol 224 (2) ◽  
pp. S589-S590
Author(s):  
Bronwyn S. Bedrick ◽  
Carly O'Donnell ◽  
Christine Marx ◽  
Hayley Friedman ◽  
Ebony B. Carter ◽  
...  
Keyword(s):  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy ◽  
Therapy Treatment

scholarly journals The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting

2017 ◽  
Vol 176 ◽  
pp. 133-138 ◽  
Author(s):  
Joseph K. Eibl ◽  
Graham Gauthier ◽  
David Pellegrini ◽  
Jeffery Daiter ◽  
Michael Varenbut ◽  
...  
Keyword(s):  
Clinical Setting ◽  
Agonist Therapy ◽  
Opioid Agonist ◽  
Opioid Agonist Therapy
Sign in / Sign up

Export Citation Format

Share Document